Janux Therapeutics (JANX) Income from Continuing Operations (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Income from Continuing Operations of 52860000.0 for Q1 2026, up 65.83% year-over-year from 31876913.74 in Q1 2025, and down 65.47% quarter-over-quarter from 31946000.0 in Q4 2025.
Powered by 
Analysis
Janux Therapeutics (JANX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Income from Continuing Operations for 7 consecutive years, with 52860000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 65.83% year-over-year to 52860000.0; the TTM figure through Mar 2026 stood at 348498000.0 (up 56.94% YoY), while the FY2025 annual figure was 143221000.0, up 66.74% from the prior year.
- Income from Continuing Operations retreated to 52860000.0 in Q1 2026 per JANX's latest filing, from 31946000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11758000.0 in Q4 2023 and bottomed at 341545000.0 in Q3 2024.
- Historically, Income from Continuing Operations has averaged 102802235.29 across 5 years, with a median of 54414000.0 in 2022.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 2020.58% — and 2026, when it soared 65.83%.
- Janux Therapeutics' Income from Continuing Operations stood at 16409000.0 in 2022, then climbed by 28.34% to 11758000.0 in 2023, then plunged by 71.93% to 20216000.0 in 2024, then plunged by 58.02% to 31946000.0 in 2025, then slumped by 65.47% to 52860000.0 in 2026.
- Business Quant data shows JANX's Income from Continuing Operations at 52860000.0 in Q1 2026, 31946000.0 in Q4 2025, and 131157000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Janux Therapeutics | 1.27 Bn | 1.27 Bn | - | -21.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.97 Mn |
| Mar 31, 2026 | -24.36 Mn |
| Dec 31, 2025 | -31.95 Mn |
| Sep 30, 2025 | -24.31 Mn |
| Jun 30, 2025 | -33.86 Mn |
| Mar 31, 2025 | -23.51 Mn |
| Dec 31, 2024 | -20.22 Mn |
| Sep 30, 2024 | -28.06 Mn |
| Jun 30, 2024 | -5.96 Mn |
| Mar 31, 2024 | -14.76 Mn |
| Dec 31, 2023 | -11.76 Mn |
| Sep 30, 2023 | -11.57 Mn |
| Jun 30, 2023 | -17.51 Mn |
| Mar 31, 2023 | -17.46 Mn |
| Dec 31, 2022 | -16.07 Mn |
| Sep 30, 2022 | -16.70 Mn |
| Jun 30, 2022 | -16.89 Mn |
| Mar 31, 2022 | -13.41 Mn |
| Dec 31, 2021 | -13.42 Mn |
| Sep 30, 2021 | -10.77 Mn |